{"id":539072,"date":"2021-09-16T08:04:21","date_gmt":"2021-09-16T12:04:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\/"},"modified":"2021-09-16T08:04:21","modified_gmt":"2021-09-16T12:04:21","slug":"seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\/","title":{"rendered":"Seven Abstracts to be Presented on Evofem Biosciences’ Vaginal pH Modulator"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SAN DIEGO<\/span>, Sept. 16, 2021<\/span> \/PRNewswire\/ —\u00a0Evofem Biosciences, Inc., (NASDAQ:\u00a0EVFM) today announced that seven data sets from clinical trials of Phexxi\u00ae (lactic acid, citric acid and potassium bitartrate) and EVO100 will be presented at four medical society meetings in October 2021<\/span>.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Evofem
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“We look forward to providing important clinical insights related to the robust data supporting Phexxi,” said Brandi Howard<\/span>, PhD, Evofem Biosciences’ Head of Medical Affairs and Lead for the AMPOWER and AMPREVENCE trials. “There is tremendous interest nationally and internationally from healthcare providers to learn more about Evofem’s vaginal pH modulator, Phexxi, for\u00a0 contraception and for investigational EVO100 for protection from certain sexually transmitted infections including chlamydia and gonorrhea.” <\/p>\n

The 2021 fall medical society meeting season begins with two posters at the Society of Family Planning<\/b>(SFP) Annual Meeting<\/b>:\u00a0<\/p>\n

\n\n\n\n\n\n
\n

\n
\n Abstract <\/b>
\n Title*<\/b>:\u00a0<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Genitourinary symptoms by frequency of use of a vaginal pH modulator: Results from the phase 3 AMPOWER trial<\/i>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Authors:<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n Teresa Becker, MD; Kelly Culwell, MD, MPH; Clint Dart, MS; Brandon Howard, PhD<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Poster Number:<\/b>\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n P46<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Category<\/b>: \u00a0\u00a0\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n Contraception\u00a0<\/b><\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\u00a0<\/p>\n

\n\n\n
\n

\u00a0<\/p>\n

\n *Evofem’s poster was among the highest scored posters accepted by SFP
and is eligible to receive an award at the conference.
Winners will be announced at the end of the conference.<\/span>\n <\/p>\n

\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\u00a0<\/p>\n

\n\n\n\n\n\n
\n

\n
\n Abstract Title:\u00a0<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Pooled safety data from two phase 3 trials of a vaginal pH modulator: Results from AMPOWER and AMP001<\/i>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Authors:<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Teresia Lee, MD; Kelly Culwell, MD, MPH; Clint Dart, MS; Brandon Howard, PhD<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Poster Number:<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n P50<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Category<\/b>:<\/span>\n <\/p>\n<\/td>\n

\n

\n Contraception\u00a0<\/b><\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

Accepted scientific posters will be showcased in a Poster reception on\u00a0September 27, 2021, from 6:00pm-7:00pm ET<\/span>.\u00a0The SFP virtual Annual Meeting will be held October 1-2, 2021<\/span>. <\/p>\n

Dr. Howard will present three posters at the American Society for Reproductive Medicine (ASRM) 77th Scientific Congress & Expo<\/b> in Baltimore, Maryland<\/span> on Wednesday, October 20, 2021<\/span>:<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\n
\n Abstract Title:\u00a0\u00a0\u00a0<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Timing of On-Study Pregnancies with a Vaginal pH Modulator in the Phase 3 AMPOWER Trial<\/i>
\n \u00a0<\/i>
\n (<\/i>
\n 10797)<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Authors:<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n B. Todd Chappell, MD; Kelly Culwell, MD, MPH; Clint Dart, MS; Brandon Howard, PhD<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Poster Number:<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n P-436\u00a0<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Date:<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n Wednesday, October 20, 2021\u00a0<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Poster Session<\/b>: <\/span>\n <\/p>\n<\/td>\n

\n

\n Contraception<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n \n <\/td>\n<\/tr>\n
\n

\n
\n Abstract Title:\u00a0\u00a0\u00a0<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Side effects by frequency of use with EVO100 vaginal gel: results from the Phase 2B\/3 AMPREVENCE trial (10790)<\/i>\u00a0<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Authors:<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n Ronald Surowitz;\u00a0Kelly Culwell, MD, MPH; Clint Dart, MS; Brandon Howard, PhD<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Poster Number:<\/b>\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n P-726\u00a0<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Date:<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n Wednesday, October 20, 2021\u00a0<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Poster Session<\/b>: <\/span>\n <\/p>\n<\/td>\n

\n

\n Public Health and Reproduction<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n \n <\/td>\n<\/tr>\n
\n

\n
\n Abstract Title:\u00a0\u00a0<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Incorporating direct patient health outcomes into clinical trials for the prevention of urogenital chlamydia trachomatis infection: analysis of a novel endpoint in a clinical trial of EVO100\u00a0\u00a0<\/i>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Authors:<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n John Powers; Kelly Culwell, MD, MPH; Clint Dart, MS; Brandon Howard, PhD<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Poster Number:<\/b>\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n P-720<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Date:<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n Wednesday, October 20, 2021\u00a0<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Poster Session<\/b>: \u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n Public Health and Reproduction<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

These abstracts will be published online in the\u00a0Fertility and Sterility<\/i>\u00a0Abstract Supplement in September 2021<\/span>. Poster abstracts will also be available in the ASRM On-Demand Congress content.<\/p>\n

At AMCP Nexus 2021, <\/b>B. Todd Chappell<\/span>, MD, FACOG, will give an Encore presentation of a poster detailing results of the Phase 2B<\/span>\/3 AMPREVENCE study. \u00a0This double-blinded, placebo-controlled study met its primary and secondary efficacy endpoints, with statistically significant reductions in the risk of chlamydia and gonorrhea infections in women.<\/p>\n

\n\n\n\n\n\n\n
\n

\n
\n Abstract title:\u00a0\u00a0\u00a0<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Efficacy and Safety of EVO100 for Prevention of Chlamydia and Gonorrhea: Results From AMPREVENCE, a Phase 2B\/3 Study\u00a0<\/i>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Authors:<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n B. Todd Chappell, MD; Scott Mollan, MS, MBA; Kelly Culwell, MD, MPH; Brandon Howard, PhD<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Poster Number:<\/b>\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n A3<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Date:<\/b>\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n Wednesday, October 20 <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Time: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n 12:00 – 2:30pm MT<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

Dr. Chappell, an\u00a0obstetrician\/gynecologist practicing at\u00a0Adams\u00a0Patterson Gynecology & Obstetrics\u00a0in\u00a0Memphis,\u00a0Tennessee, was the lead author of the pivotal AMPREVENCE manuscript<\/a>\u00a0which was published in the American Journal of Obstetrics and Gynecology<\/i>\u00a0(AJOG) in 20211<\/sup>. <\/p>\n

Finally, at the International Federation of\u00a0Gynecology\u00a0and Obstetrics<\/b>\u00a0(<\/b>FIGO) XXIII World\u00a0Congress of Obstetrics and Gynecology to <\/b>be held virtually October 21-28, 2021<\/span>, Dr. Howard will present a poster highlighting efficacy of the contraceptive vaginal gel Phexxi\u00ae (lactic acid, citric acid and potassium bitartrate) when used as directed in the pivotal Phase 3 AMPOWER study.\u00a0 <\/p>\n

\n\n\n\n\n
\n

\n
\n Abstract title:\u00a0<\/b>\u00a0\u00a0\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Perfect-use efficacy results with Phexxi\u00ae from the Phase 3 AMPOWER study<\/i>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Authors:<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n B. Todd Chappell, MD; Kelly Culwell, MD, MPH; Clint Dart, MS; Brandon Howard, PhD<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Poster Number:<\/b>\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n 0610<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

This abstract\u00a0<\/b>will be published as a supplement to FIGO’s International Journal of Gynaecology and Obstetrics<\/i>.<\/p>\n

\n About Evofem Biosciences
<\/b>Evofem Biosciences, Inc., (NASDAQ:\u00a0EVFM) is developing and commercializing innovative products and product candidates to address unmet needs in women’s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). For more information, please visit evofem.com<\/a>.<\/p>\n

\n Phexxi\u00ae<\/sup>\u00a0is a registered trademark of Evofem Biosciences, Inc.<\/i>\n <\/p>\n

\n
\n 1<\/sup>\u00a0<\/b>Chappell B.T. et al<\/i>. EVO100 prevents chlamydia and gonorrhea in women at high risk of infection. American Journal of Obstetrics and Gynecology<\/i>, Volume 225, Issue 2,\u00a0August 2021, Pages 162.e1-162.e14. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0002937821001563<\/a>\u00a0<\/p>\n

\n Investor Relations Contact
<\/b>
\n Amy Raskopf<\/span>
\n
Evofem Biosciences, Inc.
araskopf@evofem.com<\/a><\/u>
Mobile: (917) 673-5775<\/p>\n

\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator-301378506.html<\/a><\/p>\n

SOURCE Evofem Biosciences, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SAN DIEGO, Sept. 16, 2021 \/PRNewswire\/ —\u00a0Evofem Biosciences, Inc., (NASDAQ:\u00a0EVFM) today announced that seven data sets from clinical trials of Phexxi\u00ae (lactic acid, citric acid and potassium bitartrate) and EVO100 will be presented at four medical society meetings in October 2021. “We look forward to providing important clinical insights related to the robust data supporting Phexxi,” said Brandi Howard, PhD, Evofem Biosciences’ Head of Medical Affairs and Lead for the AMPOWER and AMPREVENCE trials. “There is tremendous interest nationally and internationally from healthcare providers to learn more about Evofem’s vaginal pH modulator, Phexxi, for\u00a0 contraception and for investigational EVO100 for protection from certain sexually transmitted infections including chlamydia and gonorrhea.” The 2021 fall medical society meeting season begins … <\/p>\n

Continue reading “Seven Abstracts to be Presented on Evofem Biosciences’ Vaginal pH Modulator”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-539072","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSeven Abstracts to be Presented on Evofem Biosciences' Vaginal pH Modulator - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Seven Abstracts to be Presented on Evofem Biosciences' Vaginal pH Modulator - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO, Sept. 16, 2021 \/PRNewswire\/ —\u00a0Evofem Biosciences, Inc., (NASDAQ:\u00a0EVFM) today announced that seven data sets from clinical trials of Phexxi\u00ae (lactic acid, citric acid and potassium bitartrate) and EVO100 will be presented at four medical society meetings in October 2021. “We look forward to providing important clinical insights related to the robust data supporting Phexxi,” said Brandi Howard, PhD, Evofem Biosciences’ Head of Medical Affairs and Lead for the AMPOWER and AMPREVENCE trials. “There is tremendous interest nationally and internationally from healthcare providers to learn more about Evofem’s vaginal pH modulator, Phexxi, for\u00a0 contraception and for investigational EVO100 for protection from certain sexually transmitted infections including chlamydia and gonorrhea.” The 2021 fall medical society meeting season begins … Continue reading "Seven Abstracts to be Presented on Evofem Biosciences’ Vaginal pH Modulator"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-16T12:04:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/780907\/Evofem_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Seven Abstracts to be Presented on Evofem Biosciences’ Vaginal pH Modulator\",\"datePublished\":\"2021-09-16T12:04:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\\\/\"},\"wordCount\":820,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/780907\\\/Evofem_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\\\/\",\"name\":\"Seven Abstracts to be Presented on Evofem Biosciences' Vaginal pH Modulator - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/780907\\\/Evofem_Logo.jpg\",\"datePublished\":\"2021-09-16T12:04:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/780907\\\/Evofem_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/780907\\\/Evofem_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seven Abstracts to be Presented on Evofem Biosciences’ Vaginal pH Modulator\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Seven Abstracts to be Presented on Evofem Biosciences' Vaginal pH Modulator - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\/","og_locale":"en_US","og_type":"article","og_title":"Seven Abstracts to be Presented on Evofem Biosciences' Vaginal pH Modulator - Market Newsdesk","og_description":"PR Newswire SAN DIEGO, Sept. 16, 2021 \/PRNewswire\/ —\u00a0Evofem Biosciences, Inc., (NASDAQ:\u00a0EVFM) today announced that seven data sets from clinical trials of Phexxi\u00ae (lactic acid, citric acid and potassium bitartrate) and EVO100 will be presented at four medical society meetings in October 2021. “We look forward to providing important clinical insights related to the robust data supporting Phexxi,” said Brandi Howard, PhD, Evofem Biosciences’ Head of Medical Affairs and Lead for the AMPOWER and AMPREVENCE trials. “There is tremendous interest nationally and internationally from healthcare providers to learn more about Evofem’s vaginal pH modulator, Phexxi, for\u00a0 contraception and for investigational EVO100 for protection from certain sexually transmitted infections including chlamydia and gonorrhea.” The 2021 fall medical society meeting season begins … Continue reading \"Seven Abstracts to be Presented on Evofem Biosciences’ Vaginal pH Modulator\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-16T12:04:21+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/780907\/Evofem_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Seven Abstracts to be Presented on Evofem Biosciences’ Vaginal pH Modulator","datePublished":"2021-09-16T12:04:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\/"},"wordCount":820,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/780907\/Evofem_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\/","name":"Seven Abstracts to be Presented on Evofem Biosciences' Vaginal pH Modulator - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/780907\/Evofem_Logo.jpg","datePublished":"2021-09-16T12:04:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/780907\/Evofem_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/780907\/Evofem_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seven-abstracts-to-be-presented-on-evofem-biosciences-vaginal-ph-modulator\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Seven Abstracts to be Presented on Evofem Biosciences’ Vaginal pH Modulator"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/539072","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=539072"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/539072\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=539072"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=539072"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=539072"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}